You are here

Imidazenil: A Protective Agent Against Chemical Warfare Agents induced Status Epilepticus

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W81XWH-05-C-0125
Agency Tracking Number: C051-116-0155
Amount: $724,300.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: CBD05-116
Solicitation Number: 2005.1
Solicitation Year: 2005
Award Year: 2007
Award Start Date (Proposal Award Date): 2007-05-22
Award End Date (Contract End Date): 2009-05-21
Small Business Information
513 Central Avenue, 5th Floor
Chicago, IL 60063
United States
DUNS: 196399013
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 James Auta
 Assistant Professor
 (312) 355-4857
Business Contact
 Erminio Costa
Title: Distinguished Professor
Phone: (312) 413-4592
Research Institution

The overall objective of this Phase II proposal is to determine the advantages of imidazenil over diazepam or midazolam as a potential anticonvulsant agent for the prophylaxis and for the emergency treatment of organophosphate nerve agent exposure. Therefore, we will compare the dose-dependent efficacy and anticonvulsant tolerance liability of imidazenil or midazolam for protecting rats against diisopropyl fluorophosphates (DFP)-induced status epilepticus (SE) and on neuropathology using the following specific aims: Aim 1: Compare the dose-dependent efficacies of imidazenil, diazepam or midazolam administered alone or in combination with HI-6 and atropine against DFP-induced seizures or SE. Efficacy against DFP-induced SE will be evaluated by telemetric monitoring of cortical electroencephalogram (EEG), electromyogram (EMG), core body temperature and activity. Aim 2: Evaluate the dose-dependent protection elicited by imidazenil, diazepam or midazolam in combination with HI-6 and atropine on DFP-induced neuropathology. We will evaluate rat brains for neuronal degeneration using the deoxyribonucleic acid (DNA) fragmentation measurement and light microscopic histological examination. Aim 3: Compare the tolerance liability of imidazenil, diazepam or midazolam in the presence of HI-6 and atropine against DFP-induced seizures and neuropathology following a 14 day protracted treatment with increasing doses of these benzodiazepine recognition site agonists. After termination of protracted treatment, anticonvulsant efficacy will be evaluated with telemetric monitoring as described in aim 1 above. We hope that the results of these studies together with the widely published information regarding the favorable pharmacological profile of imidazenil (appendix 1), available preliminary data on the acute and chronic toxicity, and mutagenic effects of imidazenil (for details see appendix 2) will provide the rationale for future Phase III studies.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government